Yamanouchi Masayuki, Hoshino Junichi, Ubara Yoshifumi, Takaichi Kenmei, Kinowaki Keiichi, Fujii Takeshi, Ohashi Kenichi, Mise Koki, Toyama Tadashi, Hara Akinori, Kitagawa Kiyoki, Shimizu Miho, Furuichi Kengo, Wada Takashi
Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
Nephrology Center, Toranomon Hospital, Tokyo, Japan.
PLoS One. 2018 Jan 16;13(1):e0190930. doi: 10.1371/journal.pone.0190930. eCollection 2018.
There have been a limited number of biopsy-based studies on diabetic nephropathy, and therefore the clinical importance of renal biopsy in patients with diabetes in late-stage chronic kidney disease (CKD) is still debated. We aimed to clarify the renal prognostic value of pathological information to clinical information in patients with diabetes and advanced CKD.
We retrospectively assessed 493 type 2 diabetics with biopsy-proven diabetic nephropathy in four centers in Japan. 296 patients with stage 3-5 CKD at the time of biopsy were identified and assigned two risk prediction scores for end-stage renal disease (ESRD): the Kidney Failure Risk Equation (KFRE, a score composed of clinical parameters) and the Diabetic Nephropathy Score (D-score, a score integrated pathological parameters of the Diabetic Nephropathy Classification by the Renal Pathology Society (RPS DN Classification)). They were randomized 2:1 to development and validation cohort. Hazard Ratios (HR) of incident ESRD were reported with 95% confidence interval (CI) of the KFRE, D-score and KFRE+D-score in Cox regression model. Improvement of risk prediction with the addition of D-score to the KFRE was assessed using c-statistics, continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI).
During median follow-up of 1.9 years, 194 patients developed ESRD. The cox regression analysis showed that the KFRE,D-score and KFRE+D-score were significant predictors of ESRD both in the development cohort and in the validation cohort. The c-statistics of the D-score was 0.67. The c-statistics of the KFRE was good, but its predictive value was weaker than that in the miscellaneous CKD cohort originally reported (c-statistics, 0.78 vs. 0.90) and was not significantly improved by adding the D-score (0.78 vs. 0.79, p = 0.83). Only continuous NRI was positive after adding the D-score to the KFRE (0.4%; CI: 0.0-0.8%).
We found that the predict values of the KFRE and the D-score were not as good as reported, and combining the D-score with the KFRE did not significantly improve prediction of the risk of ESRD in advanced diabetic nephropathy. To improve prediction of renal prognosis for advanced diabetic nephropathy may require different approaches with combining clinical and pathological parameters that were not measured in the KFRE and the RPS DN Classification.
基于活检的糖尿病肾病研究数量有限,因此肾活检在晚期慢性肾脏病(CKD)糖尿病患者中的临床重要性仍存在争议。我们旨在阐明病理信息对糖尿病和晚期CKD患者临床信息的肾脏预后价值。
我们回顾性评估了日本四个中心493例经活检证实为糖尿病肾病的2型糖尿病患者。确定了296例活检时处于3 - 5期CKD的患者,并为其分配了两个终末期肾病(ESRD)风险预测评分:肾衰竭风险方程(KFRE,一个由临床参数组成的评分)和糖尿病肾病评分(D评分,一个整合了肾脏病理学会糖尿病肾病分类(RPS DN分类)病理参数的评分)。他们以2:1的比例随机分为开发队列和验证队列。在Cox回归模型中报告了KFRE、D评分和KFRE + D评分的ESRD发生风险比(HR)及其95%置信区间(CI)。使用c统计量、连续净重新分类改善(NRI)和综合鉴别改善(IDI)评估在KFRE中加入D评分后风险预测的改善情况。
在中位随访1.9年期间,194例患者发生了ESRD。Cox回归分析表明,KFRE、D评分和KFRE + D评分在开发队列和验证队列中都是ESRD的显著预测指标。D评分的c统计量为0.67。KFRE的c统计量良好,但其预测价值比最初报道的其他CKD队列中的预测价值弱(c统计量,0.78对0.90),并且加入D评分后没有显著改善(0.78对0.79,p = 0.83)。在KFRE中加入D评分后,仅连续NRI为阳性(0.4%;CI:0.0 - 0.8%)。
我们发现KFRE和D评分的预测价值不如报道的那样好,并且将D评分与KFRE相结合并没有显著改善晚期糖尿病肾病ESRD风险的预测。为了改善晚期糖尿病肾病肾脏预后的预测,可能需要采用不同的方法来结合临床和病理参数,这些参数在KFRE和RPS DN分类中未进行测量。